What exactly is happening inside a dog's body with multiple myeloma?

Multiple myeloma is a cancer of plasma cells, the mature white blood cells responsible for producing antibodies against infection. In this disease, one clone of plasma cells multiplies uncontrollably inside the bone marrow, crowding out normal blood cell production and often churning out a single abnormal antibody protein called an M-protein or paraprotein, which can be detected on serum protein electrophoresis (American College of Veterinary Internal Medicine, n.d.). It accounts for roughly 1 to 2 percent of all cancers diagnosed in dogs, making it uncommon but not exotic, and it tends to affect middle-aged to older dogs, with a median age at diagnosis around 8 to 9 years (Merck Veterinary Manual, 2023).

Because plasma cells live in bone marrow spread throughout the skeleton, the cancer's effects show up in several organ systems at once rather than as a single visible mass. Abnormal plasma cells can erode bone, causing lytic lesions visible on radiographs, while excess antibody protein circulating in the blood can thicken it and impair kidney filtration (Cornell Riney Canine Health Center, n.d.). This multi-system pattern is part of why veterinarians describe myeloma as a systemic disease rather than a localized tumor, and why diagnosis usually involves bloodwork, urine testing, and imaging together rather than a single test.

What are the first signs owners tend to notice at home?

Early multiple myeloma is notoriously subtle, and many owners initially chalk up the signs to normal aging. Lethargy, decreased appetite, and increased thirst and urination are among the most commonly reported early symptoms, often building gradually over weeks to months rather than appearing suddenly (Merck Veterinary Manual, 2023). Because these signs overlap with kidney disease, Cushing's disease, and simple aging, many dogs are not diagnosed until bloodwork ordered for another reason turns up abnormal total protein levels.

Bone pain and lameness are also common, since myeloma cells can weaken vertebrae and long bones enough to cause pathologic fractures in advanced cases. Some dogs develop bleeding tendencies such as nosebleeds or bruising because the abnormal antibody protein interferes with normal platelet function and clotting factors, a phenomenon veterinary hematologists call hyperviscosity syndrome when protein levels get high enough to thicken the blood (American College of Veterinary Internal Medicine, n.d.). Owners sometimes notice their dog seems 'off' in a vague way well before any single dramatic symptom appears.

What causes it, and are certain dogs more at risk?

The exact trigger for the plasma cell mutation that leads to myeloma is not well understood, and no clear environmental or dietary cause has been established in dogs. What is known is that it is a disease of aging, rarely diagnosed in dogs younger than 5 years old, and some breed patterns have been reported, including a possible predisposition in German Shepherd Dogs in certain case series, though large-scale genetic studies are still limited (Merck Veterinary Manual, 2023).

Unlike some canine cancers with known viral or chemical associations, multiple myeloma does not currently have an identified preventable cause, which means there is no established way for owners to reduce risk through diet or lifestyle. This makes routine senior wellness bloodwork, generally recommended annually for dogs over 7 years old by organizations like AAHA, one of the more practical tools for catching abnormal protein levels before clinical signs become severe (American Animal Hospital Association, 2023).

How do veterinarians actually confirm the diagnosis?

No single test diagnoses multiple myeloma; veterinarians typically rely on a set of criteria requiring at least two of four findings: a monoclonal gammopathy on serum protein electrophoresis, more than 20 percent plasma cells in a bone marrow aspirate, lytic bone lesions on radiographs, and Bence Jones proteinuria, meaning abnormal light-chain proteins in urine (American College of Veterinary Internal Medicine, n.d.). A bone marrow aspirate or core biopsy is usually the most definitive single step, performed under sedation from the humerus or iliac crest.

Additional bloodwork including a complete blood count, chemistry panel, and calcium level helps stage the disease and predict prognosis, since high calcium and significant kidney impairment at diagnosis are both associated with a poorer outlook (Cornell Riney Canine Health Center, n.d.). Full body radiographs or CT imaging are often used to survey the skeleton for additional lytic lesions that might not be causing symptoms yet, which helps guide both treatment planning and long-term monitoring.

What treatment options actually help, and how well do they work?

Melphalan, an oral chemotherapy drug, combined with prednisone is the standard first-line treatment for canine multiple myeloma, and it produces a favorable response in a majority of treated dogs, with reported overall response rates often cited between 60 and 90 percent depending on the case series (Merck Veterinary Manual, 2023). Treatment is typically given at home as a daily or pulsed oral protocol, with regular bloodwork to monitor for the drug's main side effect, bone marrow suppression, which can lower white blood cell and platelet counts.

For dogs that don't respond to melphalan or relapse, second-line options include cyclophosphamide, doxorubicin, or newer targeted agents, though these are used less commonly and success rates drop compared to first-line therapy (Cornell Riney Canine Health Center, n.d.). Median survival times for dogs treated with melphalan-prednisone protocols are frequently reported in the range of 12 to 18 months, though individual outcomes vary widely based on kidney function, calcium levels, and how quickly treatment starts after diagnosis.

What does day-to-day home care and monitoring look like during treatment?

Dogs on melphalan therapy need periodic complete blood counts, often every one to two weeks initially, to catch dangerous drops in white blood cells or platelets before they cause illness or bleeding, since myelosuppression is the treatment's main dose-limiting side effect (American College of Veterinary Internal Medicine, n.d.). Owners are usually asked to watch for signs of infection, unusual bruising, or lethargy between visits and to keep a log of appetite, water intake, and energy level to share with the veterinary oncology team.

Kidney function requires ongoing attention as well, since myeloma-related kidney damage can be permanent even after the cancer responds to chemotherapy; some dogs benefit from prescription renal diets and fluid support alongside their cancer treatment. Pain control for bone involvement, sometimes including bisphosphonates to help protect bone density, may also be part of the daily management plan for dogs with significant skeletal lesions (Merck Veterinary Manual, 2023).

What is the long-term outlook for a dog diagnosed with this disease?

Multiple myeloma is not considered curable, but it is one of the more treatable canine cancers when caught before severe kidney damage or bone destruction sets in, with many dogs achieving remission lasting a year or more on melphalan-based therapy (Merck Veterinary Manual, 2023). Dogs with normal kidney function and calcium levels at diagnosis tend to have meaningfully better survival than those with significant organ involvement already present.

Relapse eventually occurs in most dogs, at which point second-line chemotherapy or referral to a veterinary oncologist for more advanced protocols may extend quality time further. Regular rechecks, typically including repeat protein electrophoresis and bloodwork every few months even during remission, help catch relapse early enough to adjust treatment before symptoms return in force (Cornell Riney Canine Health Center, n.d.).